Lifecore Biomedical, Inc. (Nasdaq: LFCR) and Alcon Inc. (NYSE: ALC) have entered into a wide-ranging set of agreements, including a new $150 million credit arrangement. This credit facility will enable Lifecore to repay its existing credit agreement with its current lenders while also substantially increasing the supply of hyaluronic acid that Lifecore will provide for use in Alcon's commercial products. 

In after-hours, $LFCR is currently trading at $6.14, reflecting a significant increase of $0.78 or 14.59%.

Avanos Medical, Inc. (NYSE: AVNS) has been initiated with a Buy rating by CL King, along with a price target of $31. On Monday, $AVNS closed at $23.55, experiencing an increase of $1.02 or 4.53%.

CONMED Corporation (NYSE: CNMD) has also received a Buy rating from CL King, with a price target of $140. $CNMD closed at $120.50 on Monday, demonstrating a gain of $1.54 or 1.29%.

Recursion Pharmaceuticals, Inc. (Nasdaq: RXRX) has been initiated with an Equal Weight rating by Morgan Stanley, with a price target of $8. On Monday, $RXRX closed at $8.12, showing a significant increase of $1.69 or 26.28%.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)